ZYBERNO
Stock Report
Updated Aug 26, 2026

Radiopharm Theranostics Limited (RDPTF)

Healthcare • OTC

$0.02

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
Radiopharm Theranostics Limited (RDPTF) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-208.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Radiopharm Theranostics Limited (RDPTF) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.02
Market Cap:$47.30M

Valuation Multiples (2)

P/B Ratio:1.10x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$18.18M

Price Action & Momentum (1)

% of 52-Week High:50.0%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:9.1%
Fundamental Growth Rate (g):-18.9%

Margin Analysis (1)

Ebitda Margin:-979.2%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.67x
Quick Ratio:2.67x
Cash Ratio:1.95x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-584.59x
Times Interest Earned:-584.59

Capital Structure (4)

Working Capital:24,921,003.00
Cash And Cash Equivalents:29,116,835.00
Long Term Debt:$0.00
Net Debt:-$29.12M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$3.63M
Cost Of Revenue Ttm:$3.59M

Profitability Breakdown (2)

$39.28K-$38.17M

Bottom Line Performance (3)

-$38.34M
Income Before Tax:$0.00
Ebitda Ttm:-35,578,228.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$103.29K
Interest Expense:65,300.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-979.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$86.48M
Current Assets:$39.85M
Ppe Net:53,466.00
Goodwill:0.00
Intangible Assets:$46.57M

Liability Structure (4)

Total Liabilities:43,609,972.00
Current Liabilities:14,932,985.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$42.87M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:10,400,060.00
Inventory:0.00
Accounts Payable:9,340,993.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$36.65M$0.00

Investment Activities (1)

Investing Cash Flow:$1.77M

Financing Activities (3)

Financing Cash Flow:$45.43M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.02

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.02

Book Value & Capital (2)

Book Value Per Share:$0.02
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.04x
Working Capital Turnover Ttm:0.15x

Receivables Management (2)

Receivables Turnover Ttm:0.35x
Days Sales Outstanding Ttm:1,044.75

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:948.62
Cash Conversion Cycle:-902.86
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:9.1%
Fundamental Growth Rate (g):-18.9%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:RDPTF
Company Name:Radiopharm Theranostics Limited
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:2.36B
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 23:02:22 UTC
Data Timestamp:2026-08-26T23:02:22.168220
Scroll to Top